Biological
S-531011
S-531011 is a biological therapy with 2 clinical trials. Currently 1 active trials ongoing.
Total Trials
2
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Active Trials
1(50%)
Phase Distribution
Ph phase_1
2
100%
Phase Distribution
2
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution2 total trials
Phase 1Safety & dosage
2(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
2
all time
Status Distribution
Active(2)
Detailed Status
Not yet recruiting1
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
2
Active
1
Success Rate
N/A
Most Advanced
Phase 1
Trials by Phase
Phase 12 (100.0%)
Trials by Status
not_yet_recruiting150%
recruiting150%
Recent Activity
1 active trials
Showing 2 of 2
not_yet_recruitingphase_1
A Multicenter, Phase Ib/II Clinical Trial to Evaluate the Efficacy and Safety of Concurrent Combination Therapy of S-531011 Plus Fruquintinib or S-531011 Plus Fruquintinib Plus Pembrolizumab in Patients With MSS/pMMR Colorectal Cancer
NCT07591597
recruitingphase_1
S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors
NCT05101070
Clinical Trials (2)
Showing 2 of 2 trials
NCT07591597Phase 1
A Multicenter, Phase Ib/II Clinical Trial to Evaluate the Efficacy and Safety of Concurrent Combination Therapy of S-531011 Plus Fruquintinib or S-531011 Plus Fruquintinib Plus Pembrolizumab in Patients With MSS/pMMR Colorectal Cancer
NCT05101070Phase 1
S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors
All 2 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 2